GE HealthCare management check
GEHC · Health Care · Health Care Equipment · CEO Peter J Arduini
Filings as of
Closest peers in Health Care Equipment
- 153ISRGIntuitive Surgical72
- 158ABTAbbott Laboratories72
- 162SYKStryker Corporation71
- 185IDXXIdexx Laboratories69
- 199BSXBoston Scientific68
- 250RVTYRevvity64
- 284RMDResMed63
- 286GEHCGE HealthCare62
- 322STESteris60
- 353BDXBecton Dickinson58
The seven checks
- GoodBeat its chosen peers
Have owners done well?
What $100 became since fiscal 2022
6566thDetail
$100 invested at the start of fiscal 2022 grew to $136, against $122 for the peer group the company picked itself.
- FlagPay moved against returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
346thDetail
Over 3 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of -0.32 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good0.9% of net income
What does the CEO cost owners?
$18.6m pay · $2.2bn net income, FY2025
5556thDetail
$18.6m of reported pay in fiscal 2025, against $2.2bn of net income.
- GoodInsiders are buying
Do they own the stock?
241,606 shares ≈ $17.0m
6 mo: ▲ $642k bought · ▼ $0 sold
5358thDetail
The CEO holds 241,606 shares, directly or through trusts (unvested awards not counted): about 0.9 years of pay. 1 insider bought $642k on the open market in the last six months, with their own money, near the lows.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares +0.0% a year; flagged above +2%
Stock pay 0.6% of revenue
5035thDetail
Diluted shares changed +0.0% a year over the last three fiscal years. Stock-based pay was 0.6% of revenue in the latest year.
- Good9 leadership filings in 3 years
Is leadership stable?
9 filings under 8-K 5.02 in 3 years
8056thDetail
9 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2022
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2022.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed March 19, 2026.
Pay tied most to Organic revenue growth*
Other key measuresAdjusted EBIT*Free cash flow*
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | — | $18.6m | $19.6m | $5.7m | $136 | $122 | $2.2bn |
| 2024 | — | $19.5m | $13.4m | $5.2m | $130 | $114 | $2.0bn |
| 2023 | — | $24.5m | $29.8m | $9.1m | $128 | $101 | $1.6bn |
| 2022 | — | $10.5m | $7.3m | $4.7m | — | — | $2.0bn |
Insiders and the CEO's stake
- President and CEO
- Peter J Arduini
- Shares held
- 241,606
- At that filing's price
- ≈ $17.0m
- Latest Form 4
- Sep 3, 2026
1 insider bought $642k on the open market in the last six months, with their own money, near the lows.
Open-market trades by officers and directors since May 21, 2026.
- BoughtKevin LoboDirector$642kMay 22, 2026
Leadership and governance on file
All 15 filings
- Nov 5, 2026Leadership change8-K 5.02
- Oct 28, 2026Leadership change8-K 5.02
- Sep 22, 2026Leadership change8-K 5.02
- Aug 18, 2026Leadership change8-K 5.02
- Jul 23, 2026Leadership change8-K 5.02
- Mar 17, 2026Leadership change8-K 5.02
- Jul 24, 2025Leadership change8-K 5.02
- Apr 15, 2024Leadership change8-K 5.02
- Feb 5, 2024Leadership change8-K 5.02
- May 9, 2023Leadership change8-K 5.02
- Mar 24, 2023Leadership change8-K 5.02
- Mar 3, 2023Leadership change8-K 5.02
- Feb 3, 2023Leadership change8-K 5.02
- Jan 4, 2023Leadership change8-K 5.02
- Dec 14, 2022Leadership change8-K 5.02
Latest shareholder vote results: May 11, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $360.0m returned to owners in buybacks and dividends, 4% of net income, and $512.0m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $17.6bn | $18.3bn | $19.6bn | $19.7bn | $20.6bn |
| Net income | $2.2bn | $1.9bn | $1.6bn | $2.0bn | $2.1bn |
| Stock-based pay | $76.0m | $67.0m | $114.0m | $125.0m | $130.0m |
| Buybacks | — | — | $0 | $0 | $200.0m |
| Dividends | $0 | $0 | $41.0m | $55.0m | $64.0m |
| Diluted shares | 454m | 454m | 458m | 459m | 458m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.